Subscribe
shutterstock_1414222322_chris_redan
Chris Redan / Shutterstock.com
6 April 2021BiotechnologyClare Roskell and Samantha Moodie

EPO’s new examination guidelines: what you need to know

A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
EPO launches Unitary Patent dashboard revealing daily take-up figures
25 July 2023   Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Europe
Pharma patent filings rise at EPO amid pandemic
5 April 2022   Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Europe
EPO launches Unitary Patent dashboard revealing daily take-up figures
25 July 2023   Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Europe
Pharma patent filings rise at EPO amid pandemic
5 April 2022   Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.

More on this story

Europe
EPO launches Unitary Patent dashboard revealing daily take-up figures
25 July 2023   Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Europe
Pharma patent filings rise at EPO amid pandemic
5 April 2022   Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.

More features

As AI shakes up pharma and biotech, can patent law keep up?
UK court clears the way for Amgen and Samsung to launch biosimilars
SK Bioscience prevails over Pfizer in pneumococcal vaccine dispute
‘It’s going to be very different’: INTA CEO shares London meeting plans
INTA confirms London as host city for Annual Meeting 2026
Illumina takes aim at rival in gene sequencing spat
Novartis tops Big Pharma in global trademark portfolios
NanoString to pay 10x Genomics $68m in global settlement